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PW1/Peg3 expression regulates key properties that
determine mesoangioblast stem cell competence
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Mesoangioblasts are vessel-associated progenitor cells that show therapeutic promise for the
treatment of muscular dystrophy. Mesoangioblasts have the ability to undergo skeletal
muscle differentiation and cross the blood vessel wall regardless of the developmental stage
at which they are isolated. Here we show that PW1/Peg3 is expressed at high levels in
mesoangioblasts obtained from mouse, dog and human tissues and its level of expression
correlates with their myogenic competence. Silencing PW1/Peg3 markedly inhibits myogenic
potential of mesoangioblasts in vitro through MyoD degradation. Moreover, lack of PW1/Peg3
abrogates mesoangioblast ability to cross the vessel wall and to engraft into damaged
myoﬁbres through the modulation of the junctional adhesion molecule-A. We conclude that
PW1/Peg3 function is essential for conferring proper mesoangioblast competence and that
the determination of PW1/Peg3 levels in human mesoangioblasts may serve as a biomarker
to identify the best donor populations for therapeutic application in muscular dystrophies.
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M
esoangioblasts (MABs) are blood vessel-associated
progenitor cells that can differentiate into mesoderm
cell types, including skeletal muscle1. When delivered
through the arterial circulation, MABs cross the blood vessel wall
and participate in skeletal muscle regeneration leading to an
amelioration of muscular dystrophies in different pre-clinical
animal models: the a-sarcoglican-null mouse, which models the
limb-girdle muscular dystrophy, the AJ mouse model of
dysferlinopathy, the mdx mouse for Duchenne muscular
dystrophy (DMD)2–5 and the golden retriever muscular
dystrophy dog6. The ability of MABs to cross the vessel wall
confers an advantage as therapeutic donor stem cells as compared
with satellite cells and myoblasts that need to be delivered directly
into the muscle tissue to properly engraft7,8. Cells with MAB-like
properties have been isolated from human adult skeletal
muscle pericytes9 and expanded under clinical-grade conditions,
providing the basis for a Phase I/II clinical trial for Duchenne
muscular dystrophy (EudraCT no. 2011-000176-33; Cossu et al.
in preparation).
Since the initial identiﬁcation of MABs in mouse embryos1, all
MABs thus far isolated from different species (mouse, dog and
human) and developmental stages have been shown to contribute
to muscle regeneration in vivo. Although alkaline phosphatase
expression can be used to identify adult human MABs in skeletal
muscle, no single unequivocal marker has been identiﬁed that
denotes MAB identity across species1,4,6,9. As a result, MABs are
deﬁned predominantly by their isolation method and functional
properties. A cross-analysis of independent microarrays
performed on different human and murine MAB populations
revealed that PW1 is expressed in MABs regardless of species
origin and age of isolation10. PW1, also identiﬁed as Peg3
(Paternally expressed gene3) was initially isolated following a
screening to identify factors involved in skeletal muscle
commitment as well as in a screen for parentally imprinted
genes11. PW1/Peg3 (hereafter referred to as PW1) is expressed at
high levels upon gastrulation and is downregulated during fetal
and perinatal development11,12. In postnatal skeletal muscle, PW1
expression is restricted to muscle satellite cells and to a
subpopulation of interstitial cells, which display myogenic
potential13–15. Moreover, PW1 expression identiﬁes multiple
adult stem and progenitor cell populations from a wide array of
adult tissues including skin, gut, blood and central nervous
system16. PW1 encodes a zinc-ﬁnger protein that has been shown
to participate in inﬂammatory- and p53-mediated cell stress
pathways17,18 as well as a mediator of b-catenin stability in the
Wnt signalling pathway19. PW1 has also been shown to function
as a transcription factor with a DNA-binding motif regulating an
array of genes involved in metabolic homeostasis20.
We report here that silencing PW1 in a polyclonal population
of murine MABs abrogates their capacity to differentiate into
skeletal muscle and inhibits their ability to cross the vessel wall
and therefore migrate towards damaged muscle. We observed
that PW1 controls MAB muscle differentiation by stabilizing
MyoD via regulation of cyclinE levels and regulates engraftment
efﬁciency by modulating the expression of molecules responsible
for trans-vessel migration, including the tight junction molecule
JAM-A. Consistent with these observations, we found that levels
of PW1 expression correlate with the myogenic and migratory
capacities of both murine- and human-derived MABs, indicating
that PW1 expression levels can be used to screen and identify
competent MABs before their use in cell therapy.
Results
PW1 characterizes MABs and their myogenic competence. We
previously generated independent microarray gene expression
proﬁles from MABs isolated from mouse and human donors with
the aim to select common markers10. Here we focused upon PW1
since it has been shown to identify adult stem and progenitor cell
populations in different tissues, including skeletal muscle13,16.
From these arrays, PW1 was found to be expressed in MABs
regardless of species and age9,10. PW1 expression in mouse, dog
and human MABs was also conﬁrmed by quantitative PCR with
reverse transcription (qRT–PCR) (Fig. 1a). Although PW1
provides a tool as a cross-species marker, we wished to
understand its role in MABs. We therefore silenced PW1
expression in a polyclonal population of adult mouse MABs
(AdmMABs) by using a lentiviral vector expressing a short
hairpin RNA sequence for PW1 (shPW1). We chose AdmMABs
since, at variance with embryonic mMABs, they spontaneously
differentiate in culture without the need of a co-culture with
myoblasts4. As shown in Fig. 1b, silencing of PW1 led to a
marked reduction of skeletal muscle differentiation. We
established 37 clones from the parental population and assessed
their myogenic competence and levels of PW1 expression. Six
clones were chosen on the basis of their different levels of
myogenic competence. We observed that clones displaying high
levels of myogenic competence (competent clones C, G and D)
expressed high levels of PW1, whereas clones with low or no
myogenic capacity (non-competent clones L, N and O) displayed
undetectable levels of PW1 (Fig. 1c,d, Supplementary Fig. 1). We
then tested the effects of PW1 silencing on the well-characterized
embryonic mouse-derived MAB clone, D16 (refs 1,2). As seen
with AdmMABs, we observed a comparable inhibition of
myogenesis following PW1 silencing (Supplementary Fig. 2a,b).
We had previously demonstrated that myogenic competence
requires Pax3 expression in embryonic-derived mMABs21. In
contrast, silencing of Pax3 in AdmMABs does not affect
myogenic competence, revealing a developmental stage-speciﬁc
requirement for Pax3 in MABs (Supplementary Fig. 3a,b).
In agreement with this observation, PW1 expression was
undetectable in Pax3 null embryonic mMABs (Supplementary
Fig. 3c,d) but present at normal levels in Pax3 silenced
AdmMABs (Supplementary Fig. 3b). These data demonstrate
that PW1 expression is tightly linked with embryonic and adult
mMAB myogenic competence, whereas Pax3 is required uniquely
for embryonic myogenic mMAB competence.
PW1 is required for MAB differentiation via MyoD. To deﬁne
the molecular pathway through which PW1 regulates MAB
myogenic competence, we examined key regulators of the
myogenic programme in shPW1 AdmMABs versus control cells
(Ctl). We observed a marked decrease in MyoD protein in the
absence of PW1 expression (Fig. 2a). In contrast, MyoD
transcripts were present and upregulated during differentiation
regardless of short hairpin RNA treatment (Fig. 2b). Consistent
with these observations, we observed that MyoD protein is
absent in non-competent AdmMAB clones, which spontaneously
lack PW1 (Fig. 2c). It has been previously demonstrated that
activation of Cdk-dependent phosphorylation of MyoD leads
to its rapid degradation and moreover, direct phosphorylation of
MyoD on Ser200 by the complex cycE–Cdk2 (cyclinE/Cyclin
dependent kinase2) regulates its stability22–24. We therefore
measured cycE protein levels in Ctl versus shPW1 AdmMABs
during myogenic differentiation. Cells were cultured in growth
conditions and then shifted to differentiation medium (DM) for
5 days. We observed that Ctl AdmMABs downregulated cycE
in DM, as expected, whereas cycE levels remained high in the
shPW1 AdmMABs (Fig. 2d). Even though levels of cycE
remained high following PW1 silencing, we noted that
they normally exit from cell cycle as demonstrated by
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50-bromo-deoxyuridine (BrdU) labelling (Fig. 2e). We therefore
investigated the possibility of cycE regulation by PW1. Since
NIH3T3 ﬁbroblasts do not express PW1 (ref. 17), proliferating
NIH3T3 cells were transiently transfected with a plasmid
expressing PW1 or with an pEGFP Ctl vector: cycE expression
was evaluated by qRT–PCR after 12 and 36 h from transfection.
We observed a marked decrease in cycE expression in response to
PW1 (Fig. 2f,g). Moreover, we observed that in ﬁbroblasts that do
not undergo a cell cycle-dependent programme of lineage
commitment, the proliferation rate was decreased two-fold
following PW1 forced expression (Fig. 2h), consistent with
previous results18. We next veriﬁed if myogenic competent
AdmMABs also displayed PW1-mediated inhibition of cycE and
subsequent regulation of MyoD activity. Therefore, we transiently
transfected AdmMABs with either PW1 or with the empty Ctl
vector pEGFP (Fig. 2i). After 24 h from PW1 transfection, we
observed that cycE was markedly downregulated (Fig. 2j). In this
case, the proliferation rate of AdmMABs overexpressing PW1
was less altered than what was observed for the PW1-NIH3T3
cells (Fig. 2k).
The cycE-dependent degradation pathway of MyoD is due to
proteasome activity22–24. We therefore interfered with this
pathway in Ctl and shPW1 AdmMabs at two different levels: at
the level of the proteasome activity by using the proteasome
inhibitor MG132 and at the level of cycE/Cdk2 activity by using
Roscovitin (a Cdk2 inhibitor). As shown in Fig. 3a,b, inhibition
of proteasome or cycE/Cdk2 function led to MyoD protein
accumulation in shPW1 AdmMABs. To conﬁrm these
observations, we tested whether ectopically expressed MyoD
would rescue differentiation in the shPW1 AdmMabs using
both wt or a phosphorylation-resistant form of MyoD (MyoD,
MyoDsp3)25. Ctl, MyoD or MyoDsp3 transduced-shPW1
AdmMABs were induced to differentiate and we observed that
only MyoDsp3 forced expression led to a complete rescue of
terminal myogenic differentiation (Fig. 3c,d). Notably, we
additionally performed the same experiments in non-competent
clones and obtained the same results (Supplementary Fig. 4). We
reasoned that MyoD forced expression did not rescue the
myogenic programme in shPW1 AdmMabs due to a high rate
of MyoD degradation (Fig. 3d). We conﬁrmed this hypothesis
by treating these cells with MG132 and observed that MyoD
protein properly accumulated when the proteasome pathway was
blocked, suggesting that in the absence of PW1 expression, the
rate of MyoD degradation is high (Fig. 3e).
AdmMABs require PW1 to cross vessels and engraft muscles.
To assess whether the absence of PW1 impairs myogenic differ-
entiation in vivo, we injected Ctl or shPW1 AdmMABs,
previously transduced with a lentiviral vector carrying nLacZ
(to improve detection), into the femoral artery of dystrophic
immunodeﬁcient scid-mdx mice (to avoid immune rejection
against the b-galactosidase). Mice were killed at both 6 h and 1
month after injection. As expected, Ctl AdmMabs gave rise to
dystrophin expressing ﬁbres 1 month after injection. In contrast,
no dystrophin expression was observed following injection of
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Figure 1 | Silencing of PW1 interferes with mesoangioblasts (MABs) muscle differentiation. (a) PW1 expression by qRT–PCR on different populations of
mouse adult (AdmMABs), human and canine MABs. Values are plotted as relative messenger RNA (mRNA) expression and normalized to GAPDH levels.
For the AdmMABs, values are expressed as fold expression relative to subpopulation of interstitial cells (PICs; ¼ 1). Each assay was performed in triplicate.
Data are represented as means±s.d. *Po0.05, ns, not signiﬁcant one-way unpaired t Test. (b) Immunoﬂuorescence analysis for PW1 (red) and for the
expression of all sarcomeric myosins (MyHC, green) on Ctl and shPW1 AdmMAB growing cells upon 5 days in differentiation medium. DAPI was used to
stain nuclei. Scale bar represents 100 and 50mm. (c) Western blot analysis of MyHC and PW1 expression on six different clones of AdmMABs isolated and
selected for the different myogenic potency. Clones have been divided in competent (C, G, D) and non-competent (L, N, O) on the basis of their myogenic
property. b-Tubulin was used to normalize the amount of loaded proteins. Polyclonal AdmMABs were used as a positive control. (d) PW1 expression by
qRT–PCR on representative clones of competent (Dþ ) and non-competent AdmMABs (N ). Values are normalized to GAPDH levels and expressed as
fold expression relative to PICs (¼ 1). NIH3T3 ﬁbroblasts were used as negative control.
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shPW1 AdmMABs (Fig. 4a,b). Notably, at 6 h post injection,
we observed that the shPW1 AdmMABs were primarily
excluded from the myoﬁbres and associated with the vessels
suggesting a possible impairment of MAB trans-vessel migration
in absence of PW1 (Fig. 5c,d). We therefore performed intra-
muscular injection of n-LacZ Ctl or shPW1 AdmMABs in the
tibialis anterior of the scid-mdx mice. We observed that 1 month
following intra-muscular cell transplantation, shPW1 AdmMABs
restored dystrophin expression in the injected area of scid-mdx
mice (Fig. 4c,d). This evidence suggests that the shPW1 MAB
myogenic competent correction by fusion with the resident
regenerating myoﬁbers, although notably in absence of PW1,
AdmMABs migrate less, as shown by clustered dystrophin
expressing myoﬁbres (Fig. 4c,d). This result most likely reﬂects
the shPW1 AdmMAB inability to properly differentiate and
express dystrophin following systemic delivery into scid-mdx
mice was primarily due to shPW1 AdmMAB impairment to cross
the vessel wall.
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We observed that while the number of b-Galþ cells in the
muscle was comparable between Ctl and shPW1 cells 6 h
following intra-femoral artery injection, only few shPW1 cells
were detected in the muscle 1 month after injection (Fig. 5a,b). To
identify the tissue distribution of the injected AdmMABs, we
stained muscle sections with PECAM (blood vessels), laminin
(ﬁber basal lamina) and b-Gal (transplanted MABs; Fig. 5c). We
observed that the majority of Ctl AdmMABs were localized in the
interstitium after 6 h, whereas the shPW1 AdmMABs were still
within the blood vessels and had not migrated inside the muscle
insterstitium (Fig. 5c,d). After 1 month, b-Gal nuclear labelling
was primarily observed in differentiated myoﬁbres following Ctl
AdmMAB injection, whereas very few labelled nuclei were
associated with myoﬁbres in the shPW1 AdmMABs-injected
mice (Fig. 5c,d).
These observations led us to propose that AdmMABs are not
able to cross the endothelium in the absence of
PW1. To address this hypothesis, we created an in vitro
environment, which allows AdmMABs to face and cross
endothelium-coated ﬁlters, partly resembling an in vivo
context. We exploited the murine endothelial cell line,
H5V for a transmigration assay. H5V cells were grown
to conﬂuence as a monolayer on gelatin-coated ﬁlters.
b-Gal-labelled Ctl and shPW1 AdmMABs were tested for
their capacity to transmigrate through the monolayer. These
experiments revealed a twofold decrease in the number of
AdmMABs crossing the monolayer in the absence of PW1
(Fig. 5e). We further noted that the ability to cross the monolayer
in this assay was present only in the competent AdmMAB clones
(Fig. 5f).
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Figure 3 | Silencing of PW1 leads to MyoD degradation via cycE/Cdk2-proteasome-dependent pathway. (a) Western blot analysis of MyoD
accumulation in Ctl and shPW1 AdmMABs following treatments with 50mM of the proteasome inhibitor MG132, for 3 and 5 h and (b) 5 mM of the cdk2
inhibitor, Roscovitin for 5 h.The þ refers to MG132- or Roscovitin-treated cells, whereas  refers to only DMSO-treated cells. GAPDH was used to
normalize the amount of loaded proteins. (c) Immunoﬂuorescence staining for myosin heavy chain (MyHC, green), MyoD (red) and nuclei (DAPI) on
shPW1 AdmMABs transduced with retroviral vector expressing wt MyoD (shPW1 MyoD AdmMABs), mutated MyoD (shPW1 MyoDsp3 AdmMABs) and
empty control vector (shPW1 Ctl AdmMABs). Scale bars, 500 and 75mm. (d) Western blot analysis of the experiment described in c: MyoD and myosin
heavy chain (MyHC) expression were checked in proliferating (GM) and differentiated (DM) shPW1 AdmMABs transduced with retrovirus expressing wt
MyoD (MyoD), mutated MyoD (MyoDsp3) and empty control vector (Ctl). GAPDH was used to normalize the amount of loaded proteins. (e) MyoD
expression, evaluated by western blot, in shPW1 AdmMABs stably transduced with the retrovirus expressing the wt MyoD (shPW1 MyoD) and treated for
5 h with the proteasome inhibitor MG132. The þ refers to MG132-treated cells, whereas  refers to only DMSO-treated cells. GAPDH was used to
normalize the amount of loaded proteins.
Figure 2 | PW1 is necessary for MAB myogenic competence and negatively regulates cyclinE expression. (a) Western blot for PW1 and myogenic
markers expressed by Ctl and shPW1 AdmMABs. GAPDH was used to normalize. GM, growing medium; DM, differentiation medium. (b) MyoD expression
by qRT–PCR on Ctl and shPW1 AdmMABs in GM and DM. Values are plotted as relative fold expression and normalized to GAPDH expression. Each assay
was performed in triplicate. Data are represented as means ± s.d. ****Po0.0001, NS, not signiﬁcant one-way unpaired t-test. (c) Western blot for PW1
and MyoD expression on non-competent (L, N, O) and competent (C, G, D) AdmMAB clones. b-Tubulin was used to normalize. (d) Western blot for cycE
expression in Ctl versus shPW1 AdmMABs in growing and differentiating conditions. GAPDH was used to normalize. (e) 50-bromo-deoxyuridine (BrdU)
incorporation assay for Ctl and shPW1 AdmMABs. Each assay was performed in triplicate. Data are represented as means± s.d. ***Po0.0005, NS, not
signiﬁcant one-way unpaired t-test. (f,g) Real time analysis showing PW1 (f) and cycE (g) levels in NIH3T3 cells transfected with plasmid expressing PW1
(PW1) or an empty vector, as control (pEGFP) after 12 (12 h) and 36 h (36 h) from the transfection. Values are plotted as relative fold expression and
normalized to GAPDH expression. Each assay was performed in triplicate. (h) BrdU incorporation assay on transfected NIH3T3 mouse ﬁbroblasts. (i,j) Real
time analysis showing PW1 (i) and CycE (j) levels on AdmMABs. Cells have been transiently transfected with plasmid expressing PW1 (PW1) and an
empty vector, as control (pEGFP). Cells have been analysed after 12 (12 h) and 24 h (24 h) from the transfection. Values are plotted as relative fold
expression and normalized to GAPDH expression. Each assay was performed in triplicate. (k) BrdU incorporation assay on transfected AdmMABs by
incubating with 50mM BrdU for 1 h, just before being stopped for the following qRT–PCR analysis. Each assay was performed in triplicate. All data are
represented as means ± s.d. *Po0.05, **Po0.005, ***Po0.0005, ****Po0.0001, NS, not signiﬁcant, one-way unpaired t-test.
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To understand the basis of the impairment of migration and
the dynamics of MAB transmigration through endothelial cells in
the absence of PW1, we used live-cell imaging by confocal
microscopy to follow this process at cellular level. Both Ctl and
shPW1 AdmMABs were treated with a 6-carboxyﬂuorescin
diacetate to allow MABs crossing the endothelial monolayers
in vitro. We found that while shPW1 AdmMABs make contact
with the endothelium, by 14 h, they are unable to cross the
monolayer and retain a spherical shape. In contrast, Ctl
AdmMABs are able to elongate pseudopods through the
endothelial monolayer and start to transmigrate (Fig. 6a). To
unravel the possible molecular mechanism at the basis of this
phenomenon, we performed a microarray analysis (Afﬁmetrix)
comparing Ctl versus shPW1 AdmMABs. We focused on the
most differentially expressed genes between shPW1 and Ctl
AdmMABs. As shown in Supplementary Fig. 5a, we conﬁrmed
that cycE1 (CCNE1) and cycE2 (CCNE2) were upregulated in the
absence of PW1. Siah1B, which has been described to bind PW1
in the p53-pathway18, is upregulated in the shPW1 AdmMABs.
In addition, effectors underlying MAB homing represented by
SDF1 (CXCL12) and its receptor (CXCR4)26 were deregulated in
shPW1 AdmMABs. These results provide a mechanistic basis for
MAB impairment to home towards damaged muscle.
Intriguingly, in shPW1 AdmMABs, we observed a
downregulation of muscular M-Cadherin (CDH15) and an
upregulation of N-Cadherin (CDH2), normally expressed in
neural and mesoderm cells, including undifferentiated myoblasts.
Among the different adhesion molecules potentially involved in
MAB extravasation, we focused upon the adhesion molecule
JAM-A since it is upregulated in the absence of PW1
(Supplementary Fig. 5a). JAM-A is a tight junction molecule
expressed primarily in endothelial and epithelial cells, leukocytes,
dendritic cells and platelets. We found this result particularly
intriguing as we recently demonstrated that JAM-A inhibition in
endothelial cells reduces junction tightening, thus allowing MAB
extravasation27. We therefore investigated whether PW1, through
JAM-A repression, has a role in AdmMAB vessel transmigration.
We conﬁrmed that JAM-A was upregulated in shPW1
AdmMABs as compared with Ctl cells, both at messenger RNA
(Supplementary Fig. 5b) and an even more pronounced difference
at the protein level (Fig. 6b and Supplementary Fig. 5c). Notably,
the non-competent AdmMAB clones (that is, the N ) showed
the same regulation pattern of JAM-A (Supplementary Fig. 5d,e).
We therefore performed a transmigration assay on Ctl and
shPW1 AdmMABs pre-incubated with a blocking antibody for
JAM-A (BV11) and an IgG as control. The interference with
JAM-A in the shPW1 AdmMABs resulted in a 1.5-fold rescue in
the capacity of shPW1 AdMABs to transmigrate (Fig. 6c).
In addition, a comparable rescue of AdmMAB ability to
transmigrate was achieved in non-competent N AdmMAB
clone following JAM-A blocking antibody (Supplementary
Fig. 5f).
To assess if this rescue also occurs in vivo, shPW1 AdmMABs
nLacZ were pre-incubated with the JAM-A blocking antibody
(BV11) or an IgG control, followed by injection into the femoral
artery of dystrophic immunodeﬁcient scid-mdx mice, which were
then killed 6 h after injection. As shown in Fig. 6d,e, JAM-A
function impairment in shPW1 AdmMABs led to a decrease in
the percentage of shPW1 AdmMABs inside the vessels and to an
increase of their presence in the interstitium, thus suggesting a
rescue in their ability to transmigrate even in vivo, 6 h after
transplantation.
6 h6 h
DAPI Laminin β-Gal  Dystrophin
DA
PI
 L
am
in
in
 
β-G
al
 D
ys
tro
ph
in
1 mo1 mo
shPW1 AdmMABs
shPW1 AdmMABs
shPW1Ctl
kDa
250
250
MyHC
Dystrophin
Ctl AdmMABs
Ctl AdmMABs
MyHC
Dystrophin
C+1 mo6 h1 mo6 h
Ctl shPW1
kDa
250
250
C–
Figure 4 | PW1-silenced MABs do not rescue the dystrophic phenotype after intra-arterial transplantation in scid-mdxmouse. (a) Immunoﬂuorescence
staining for laminin (green), dystrophin (red), b-Gal (pink) and nuclei (DAPI, blue) on serial transverse sections of gastrocnemius muscle, 6 h and 1 month
after intra-femoral artery injection of n-LacZ Ctl and shPW1 adult murine MABs (AdmMABs) into scid-mdx mice. Scale bar, 100mm. n¼4 for each group.
(b) Western blot analysis of dystrophin expression in transplanted scid-mdx muscles, 6 h and 1 month (1mo) after cell transplantation. Cþ is a wt muscle,
used as a positive control for Dystrophin expression; C is an mdx-not transplanted muscle, representing the negative control for dystrophin expression.
The expression of all the sarcomeric myosins, MyHC, was used to normalize the amount of loaded proteins. The Cþ was loaded 10 times less to avoid Ab
titration and photo bleaching. (c) Immunoﬂuorescence staining for laminin (green), dystrophin (red), b-Gal (pink) and nuclei (DAPI, blue) on the
transplanted tibialis anterior muscle, 1 month after intra-muscular injection of n-LacZ Ctl and shPW1 adult murine MABs (AdmMABs) into scid-mdx mice.
n¼4 for each group. Scale bar, 500mm. (d) Western blot analysis of dystrophin expression in transplanted scid-mdx muscles, 1 month after cell
transplantation. The expression of all the sarcomeric myosins, MyHC, was used to normalize the amount of loaded proteins.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7364
6 NATURE COMMUNICATIONS | 6:6364 | DOI: 10.1038/ncomms7364 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Overall, these data highlight a fundamental role of PW1 for the
other key feature of MABs: absence of PW1 impairs MAB ability
to cross the vessel wall and reach the muscle through a
mechanism that leads to the upregulation of JAM-A.
PW1 regulates JAM-A by a direct binding to its promoter.
PW1 has recently been shown to function as a transcription
factor with a DNA-binding motif AGTnnCnnnTGGCT20. Our
work suggests a mechanism in which PW1 regulates cycE
and JAM-A. Using the Genomatix Matinspector software, we
identiﬁed two different regions on the minus strand of the cycE
promoter containing the core sequences necessary for PW1
binding. However, due to a480% GC content, we were unable to
obtain reproducible data conﬁrming that PW1 directly binds to
these sites. Nevertheless, we measured the luciferase activity in
NIH3T3 cells co-transfected with pLuciferase-cycE  94/þ 263
promoter28 (pCE), pE2F-2 (a well-known cycE-activator)
and pGL4.76 vector (as control of transfection efﬁciency).
A signiﬁcant reduction of luciferase activity was observed when
NIH3T3 cells were co-transfected with PW1, thus suggesting a
repressive role of PW1 on cycE promoter (Fig. 7a). For JAM-A,
we identiﬁed two hypothetical binding regions in the JAM-A
promoter (JAM-A site 1 and 2) (Fig. 7b). Chromatin
immunoprecipitation (ChiP) assays performed on these PW1
binding domains on JAM-A promoter conﬁrmed a direct binding
of PW1 to JAM-A (Fig. 7b) providing a mechanistic basis for
PW1-mediated regulation of JAM-A seen in our studies.
PW1 levels correlate with human MAB competence. In the
perspective of a potential future clinical use of this marker, we
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explored whether PW1 may represent a marker of myogenic
potency also in human MABs (hMABs). In such a case it would
be possible to test PW1 expression to identify the best hMAB
donors in terms of myogenic competence and ability to cross
blood vessels. Therefore, we surveyed PW1 expression levels in
different hMAB cell lines. Twelve polyclonal populations had
been previously isolated29 and tested for their ability to
differentiate in culture. Four representative populations
(Fig. 8a) were selected and tested for PW1 expression levels by
qRT–PCR. As shown in Fig. 8b, PW1 was strongly expressed only
in myogenic competent populations of hMABs. In addition,
transmigration assays on human umbilical vein endothelial cells
(HUVECs) performed on both competent (02XY and 27XY) and
non-competent (32XY and 03XY) differentiating hMABs
conﬁrmed that the ability to cross the vessel wall strongly
correlated with levels of human JAM-A (Fig. 8c,d). We also
performed the transmigration assay on competent (02XY and
27XY) versus non-competent (32XY and 03XY) hMABs
pre-incubated with a blocking antibody speciﬁc for the human
JAM-A (BV16) and an IgG as control. The interference with
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human JAM-A in the non-competent hMABs resulted in almost
twofold rescue in their capacity to transmigrate (Fig. 8e). Taken
together, these data conﬁrm the utility of PW1 as a screening
molecule/biomarker in future cell therapy protocols on the basis
of MAB transplantation for muscle disorders.
Discussion
In the last decade, MABs have been isolated from different species
(mouse, dog and human) at different developmental stages (from
mouse embryo to adult humans, including also iPS cells)1,4,6,9,30.
Extensive analyses have shown that MABs can differentiate into
skeletal muscle and cross the vessel wall to target the damaged
muscle following systemic injection2,4–6,9. These key properties
have provided the foundation for testing MABs as a medicinal
product for stem cell-mediated therapies. Even though these cells
are being tested in clinic, it has been a challenge to determine,
without lengthy studies, both whether different preparations of
MABs share a high level of competence and what may account for
the variability of competence between individual preparations.
Microarray analyses performed on different MABs revealed that
PW1 is expressed in all MABs isolated so far. The utility of PW1
as a marker of MAB competence proposed here is consistent with
the recent observation that PW1 can be used to identify multiple
adult stem and progenitor cell populations in different tissues16.
Silencing of PW1 in a polyclonal population of adult mouse
MABs interfered with the two main features of these cells: shPW1
AdmMABs showed not to be able to differentiate in skeletal
muscle and to cross the vessel wall. These results were also
veriﬁed in different clones of embryonic and adult mouse MABs.
Previous work from our laboratory showed that the paired
box/homeodomain transcription factor Pax3 is necessary
for embryonic mesoangioblast differentiation21. Surprisingly,
silencing of Pax3 in the polyclonal population of AdmMABs
did not lead to any phenotype or change in terms of muscle
differentiation. Although our data revealed that Pax3 acts
upstream of PW1 in regulating embryonic MAB skeletal
differentiation (Supplementary Fig. 2c), this is not the case in
adult mMABs. We propose that Pax3 is only required for
embryonic myogenic competence whereas PW1 is required at all
developmental stages. As the absence of PW1 interferes with
MAB function, we also investigated the possible mechanisms
through which PW1 may act. PW1 is a multidomain protein that
contains 12 Cys2His2 Kruppel-type zinc-ﬁnger motifs as well as
two proline-rich periodic repeats which predict the ability of
binding to DNA11. We demonstrated previously that PW1
regulates two key cell stress pathways via interaction with the
TNF receptor-associated factor2 (TRAF2) and p53-mediated cell
death through direct interaction with Siah1 (Seven in absentia
homolog1) and Bcl2-associated X (BAX) proteins17,18. PW1 was
also demonstrated to inhibit Wnt signalling by promoting
b-catenin degradation19. Here, we demonstrate that the absence
of PW1 causes a block in mesoangioblast myogenic
differentiation through a sustained cycE expression that, in
turns, drives MyoD to degradation via the proteasome machinery.
Nevertheless, the levels of MyoD in proliferating Ctl AdmMABs,
which express high levels of cycE, suggests that cycE acts in
concert with other regulatory pathways in mediating the level of
MyoD in shPW1 AdmMABs. We note, however, that inhibition
of the CyclinE-cdk2 activity through Roscovitin treatment is
sufﬁcient to rescue MyoD protein in growing shPW1 cells, thus
demonstrating that this pathway has a major role in MABs.
Mesoangioblasts are able to cross the vessel wall, which
provides an advantage over satellite cells as a donor stem cell for
systemic cell therapy in treating muscular dystrophies. We
observed that PW1 silencing leads to a major adhesion to the
endothelium preventing AdmMABs extravasation. The micro-
array analysis comparing Ctl and shPW1 cells revealed marked
changes in the levels of gene expression underlying cell adhesion
and cellular homing26. We focused on JAM-A in this study as
endothelial JAM-A inhibition increases MAB transmigration
upon systemic delivery27. Surprisingly, we observed a robust
increase of JAM-A in the absence of PW1 and a corresponding
loss of trans-vessel migration capacity (Fig. 5e) that can be
rescued following JAM-A interference (Fig. 6d) in the shPW1
AdmMABs. Taken together, these data suggest that PW1 acts
upstream in the JAM-A pathway, thus inﬂuencing MAB
competence to cross blood vessel wall.
A recent report demonstrated that PW1 can act
as a transcription factor with the DNA-consensus motif
(AGTnnCnnnTGGCT) where PW1 is able to bind and repress
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speciﬁc target genes in embryonic brain20. Our analyses of the
cycE promoter identiﬁed two different regions present on the
minus strand of the cycE promoter, containing the core sequence
necessary for PW1 binding. Although we were unable to
demonstrate a direct binding, we observed a signiﬁcant
reduction of cycE promoter activity following PW1 expression
(Fig. 5f). In addition, we identiﬁed two PW1 binding regions in
JAM-A promoter (JAM-A site 1 and 2) that are directly bound by
PW1, thus providing a mechanistic basis for PW1-mediated
regulation of JAM-A seen in our studies. While PW1 has been
shown to exert numerous non-transcriptionally mediated events,
our results provide a mechanistic framework in which PW1 acts
at least in part as transcription factor to confer key properties to
MABs.
Among the multiple obstacles in using allogeneic cell
transplantation for therapeutic ends, a key challenge is to identify
the most appropriate donor cell. In addition to requirements
related to the immune system such as HLA compatibility31, the
optimal donor cell must cross the vessel wall with high efﬁciency
and once resident in the damaged muscle tissue, it must be able to
participate in the myogenic programme. At present, screening the
competence of each preparation of MABs is time consuming and
costly requiring both in vitro and ultimately in vivo assays. The
striking correlation between the level of PW1 expression in MABs
and their ability to differentiate into muscle and to cross the
endothelium in numerous cell preparations across species and age
suggests that assessing PW1 levels can substitute as rapid and
single step assay for screening donor cell preparations for
therapeutic value. Since PW1 expression identiﬁes multiple
adult stem/progenitor cell populations, we also propose that
PW1 is not only a marker, but also regulates competence in other
stem cells, such as neural and skin stem cells and can be used as a
pre-clinical screening tool in a larger stem cell therapy-based
context. Future studies will shed light on this possibility, thus
broadening and reinforcing the signiﬁcance of this study.
Methods
Cell cultures and drug treatments. We used well-established mouse adult
mesoangioblasts (AdmMABs) and D16 embryonic mMAB cell line1,4,29. These
cells were maintained in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Sigma)
with 20% fetal bovine serum (FBS, Lonza), 2mM L-glutamine, 100 IUml 1
penicillin and 100mgml 1 streptomycin (GþPS). Muscle differentiation was
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induced, after 24 h in growing medium (GM), by incubating cells in DMEM with
2% horse serum (Lonza) and Gþ PS. Cell cultures were incubated at 37 C and 5%
CO2. For D16 muscle differentiation, D16 cells were co-cultured with the L6 rat
myoblasts at a 1:10 ratio. 37 clones were isolated from the polyclonal population of
AdmMABs by limiting dilution. Cells have been diluted and one-cell-per-96-wells
plated. Clones were selected on the basis of their differentiation capacity and
among these, six most representative ones have been chosen: non-competent
clones (with a limited differentiation ability) were named L, N, O; competent
clones (with a remarkable differentiation ability) were named C, D, G.
Human mesoangioblasts (hMABs) were isolated from muscle biopsies under
the protocol ‘Evaluation of regenerative properties of human mesoangioblasts’,
submitted to the San Raffele Ethical Committee in 2007. Once isolated human cells
have been grown in Megacell DMEM (Sigma), 5% FBS, 2mM glutamine (Sigma),
0.1mM b-mercaptoethanol (Gibco), 1% non-essential amino acids (Sigma),
5 ngml 1 human bFGF (Sigma),100 IUml 1 penicillin and 100mgml 1
streptomycin (Gþ PS). Skeletal muscle differentiation was induced seeding cells on
Matrigel-coated dishes and, after 24 h in growing medium, by incubating cells in
DMEM supplemented with 2% horse serum29. Adult dog skeletal muscle MABs
were isolated from muscle biopsies of golden retriever dogs and were maintained in
culture in DMEM (Sigma) with 20% FBS and Gþ PS. Mouse embryonic ﬁbroblasts
NIH3T3 (ATCC) and mouse H5V endothelial cells (ATCC) were grown in DMEM
with 10% FBS and Gþ PS. HEK293T (ATCC) were cultured in Iscove Modiﬁed
Eagle’s Medium (Sigma) with 10% FBS (Lonza) and GþPS. HUVECs were grown
in MCDB-131 (Gibco) with 20% FBS, 10 mgml 1 heparin (Sigma-Aldrich),
5 mgml 1 ECGS (endothelial cell growth factor human, Sigma-Aldrich) and
Gþ PS.
Proteasome inhibitor MG132 (Sigma-Aldrich) was used at 50 mM for 3 and 5 h;
Roscovitine (Calbiochem) was used at 5 mM for 5 h.
To identify proliferating cells, we performed incorporation assay with
50-bromo-deoxyuridine (BrdU; GE Healthcare Life Sciences). MABs were
incubated with 50mM BrdU for 1 h before ﬁxation.
Mice and MAB transplantation. All animals studied here were housed in
San Raffaele Scientiﬁc Institute animal house. Mice were kept in pathogen-free
conditions and all procedures were conformed to Italian law and approved by the
San Raffaele Animal Care and Use Committee. Intra-arterial cell transplantations
have been performed in 5-month-old scid-mdx female mice, previously anaes-
thetized with Avertin (Sigma). A total of 106 mMABs were diluted in 50 ml of
phosphate-buffered saline (PBS) and injected into the isolated femoral artery.
The animals were killed 6 h or 1 month after the injection, then muscles were
collected and analysed. For the in vivo rescue experiment, control and shPW1 cells
were pre-incubated with the BV11 blocking peptide and control IgG (at
20mgml 1) for 2 h before transplantation.
Lentiviral and retroviral vector production and cell transduction. The shPW1
was generated by Vectalys, Prologue Bioteck, France. Brieﬂy, a forward primer
(50-CGCGACTGTACGAATGCAAAGATTTCAAGAGAATCTTTGCATTCGTA
CAGTTTTTTTCA-30) was designed including the PW1 core sequence (50-ACT
GTACGAATGCAAAGAT-30) as well as MluI and NsiI sites for cloning. The
reverse primer was designed as following 50-AAAAAACTGTACGAATGCAAA
GATTCTCTTGAAATCTTTGCATTCGTACAGT-30 . The shPW1 was generated
by hybridization of oligonucleotides and inserted by MluI/NsiI cohesive ligation
into a pLV-H1 lentiviral plasmid containing a RNA polymerase III promoter. The
pLKO.1shPax3 and pLKO.1shCONTROL were purchased by Darmacon (Open
Biosystems). The lentiviral particles were produced by transfecting the HEK 293
cells with 32 mg of the lentiviral vectors together with the packaging plasmids
pMDL (12,5 mg), pRev (6.25 mg) and pVSV-G (9mg). After 36 h from transfection,
the supernatant was collected and concentrated following centrifugation at
20,000 r.p.m. for 2 h. For viral transductions, 105 MABs were seeded in 35-mm
dishes and infected at a multiplicity of infection of 100 with the lenti shPW1 in
polybrene presence (8mgml 1). Infection was allowed to proceed overnight. The
day after, medium was changed and the selective agent, puromicin (Sigma), was
added to the cultures.
The retroviral vectors used, pBabe Hygro, pBabeHygroMyoD and
pBabeHygroMyoDSP3, are published in ref. 25. For retroviral transductions, 105
shPW1 AdmMABs were seeded in 35-mm dishes and 1ml of retroviral stock was
added; infection was allowed to proceed overnight. After overnight incubation, the
medium was changed and the selective agent, hygromycin B (Sigma), was added to
the cultures. The MABs were transduced with third generation lentiviral vectors
expressing nuclear LacZ at the multiplicity of infection of 100, after previous
incubation with Polybrene (8 mgml 1).
Transfection. The MABs were transfected with the Lipofectamine LTX transfec-
tion reagent (Invitrogen). The NIH3T3 cells were transfected using Lipofectamine
2000 (Invitrogen). The plasmids used were the pEGFP and pEGFPW1 already
published in ref. 11.
Immunoﬂuorescence and histology. Cell cultures were washed twice with PBS
and ﬁxed with 4% paraformaldehyde at 4 C for 10min. Muscle samples were
frozen in liquid nitrogen-cooled isopentane (VWR, Italy) and serial 7-mm-thick
sections were cut with a Leica cryostat (Leica Microsystems) and ﬁxed with 4%
paraformaldehyde at 4 C for 10min.
Cells and tissue were permeabilized with 0.2% Triton X-100 (Sigma), 1% bovine
serum albumin (BSA, Sigma) in PBS for 30min at room temperature (RT), then
blocked with 10% goat serum for 30min at RT. Samples were incubated overnight
at 4 C with the following primary antibodies: mouse anti-MyHC 1:2 (MyHC;
MF20, Developmental Studies Hybridoma Bank, USA), rat anti-PECAM 1:2
(CD31- Developmental Studies Hybridoma Bank, USA), rabbit anti-b-Gal 1:500
(Cappel), mouse anti-MyoD 1:100 (Dako), rabbit anti-laminin 1:300 (Sigma),
mouse anti-dystrophin 1:50 (Monosan), goat anti-mouse VE-Cad 1:400 (Santa
Cruz). After incubation, the samples were washed with 0.2% Triton X-100, 1% BSA
in PBS and then incubated with the secondary antibodies 1:500 (Jackson
Laboratories) and 4’,6-diamidino-2-phenylindole (DAPI) 1:500 (Sigma) for 45min
at RT in PBS. After two washes, dishes or slides were mounted using ﬂuorescent
mounting medium (Dako) and watched under ﬂuorescence microscopes
(Leica-DMI6000B). For the immunostaining for PW1, the cells were ﬁxed with
4% paraformaldehyde at 4 C for 10min. After three washes, the cells were
permeabilized with methanol at  20 C for 6min and blocked with 5% goat serum
and 2% of BSA (Sigma) in PBS for 3 h at RT. Samples were incubated overnight at
4 C with PW1 antibody (1:3,000) in 5% goat serum and 2% of BSA (Sigma) in
PBS. After incubation, the samples were washed with 0.1% BSA (Sigma) in PBS for
15min at RT and 5% BSA (Sigma) in PBS for 15min at RT. Then the cells were
incubated with the secondary antibody 1:500 (Jackson Laboratories) and DAPI
1:500 (Sigma) for 2 h at RT in 5% goat serum and 2% of BSA (Sigma) in PBS. After
incubation with the secondary antibody, the samples were washed with 0.1% BSA
(Sigma) in PBS for 15min at RT and 5% BSA (Sigma) in PBS for 15min at RT,
mounted using ﬂuorescent mounting medium (Dako) and watched under
ﬂuorescence microscopes (Leica-DMI6000B).
Tissue sections were stained with eosin (Sigma) and X-gal (Invitrogen)
according to standard protocols.
Microarray. The Microarray and the following analysis were performed by the
DNA-Afﬁmetrix facility at IFOM Campus. RNA from Ctl and shPW1 AdmMABs
was isolated using commercial homogenization (QIAshredder) and puriﬁcation
(RNeasy Mini Kit) reagents (Qiagen). Quality control (QC) of the RNA samples
was performed using an Agilent Bioanalyzer 2100 (Agilent Technologies). Two
different RNA extractions were processed for each of the cell lines under analysis,
and each sample was labelled and hybridized to a Mouse Gene 1.0 ST Genechip
array according to the manufacturer’s speciﬁcations (Affymetrix). Data were
analysed using Partek Genomics Suite v6.3 software (RMA algorithm). Differen-
tially expressed genes were identiﬁed through analysis of variance, using a fold
change cut-off41.2 and a P value of 0.05. Microarray data have been deposited in
Gene Expression Omnibus (GEO) under accession code GSE64334.
Quantitative PCR with reverse transcription. Total RNA was isolated using
NucleoSpin RNA XS Kit (Macheray-Nagel) and was retro-transcribed to cDNA
with the iScript Reverse Transcription Supermix (Bio-Rad), according to the
manufacturer’s instructions. Each cDNA sample was ampliﬁed in triplicate using
the iTaq Universal SYBR Green Supermix (Bio-Rad) or the SSo Advanced SYBR
Green Supermix (Bio-Rad).
The primers used are detailed in the Supplementary Table 1.
Concerning human JAM-A qRT–PCR, 400 ng of RNA was reverse transcribed
with random hexamers (High Capacity cDNA Archive Kit; Applied Biosystems) in
accordance with the manufacturer’s instructions. cDNA (5 ng) was ampliﬁed in
triplicate in a reaction volume of 15 ml with the TaqMan Gene Expression Assay
(Applied Biosystems) and an ABI/Prism 7900 HT thermocycler. For any sample
the expression level, normalized to the housekeeping gene encoding GAPDH, was
determined with the comparative threshold cycle (Ct) method.
Western blot. Proteins were extracted with a solution composed of 1% NP40
(Sigma), 0.5% sodium deoxycholate (Sigma), 1mM PMSF (phenylmethylsulfonyl
ﬂuoride), 5mM sodium orthovanadate (Sigma), proteases and phosphatases
inhibitors. The western blot for PW1 was performed as follows. Equal amounts of
proteins were run at 100V and then transferred on nitrocellulose membranes with
the Iblot Dry Blotting System (Life Technologies) for 10min. The membrane was
blocked with 5% skimmed milk, 0.05% Tween-20 (Sigma) in PBS for 1 h while
shaking at RT and incubated with primary antibody for PW1 (1:10,000) in 5%
skimmed milk, 0.05% Tween-20 (Sigma) in PBS overnight in agitation at 4 C.
After the primary antibody incubation, the membrane was washed four times
for 10min each with 0.05% Tween-20 (Sigma) in PBS (T-PBS) at RT in agitation.
Then it was incubated with secondary antibody conjugated to peroxidase 1:10,000
(Bio-Rad) in 5% skimmed milk in T-PBS for 45min at RT in agitation. After
four washes for 10min each with T-PBS at RT in agitation, the membrane was
incubated in ECL chemiluminiscence reagents following the manufacturer’s
instructions (Amersham). For all the other markers, the western blot was per-
formed as follows. Equal amounts of proteins were run at 100V and once the
proteins were separated, the gel was transferred on nitrocellulose membranes in
according with each molecular weight. The membrane was blocked with 5%
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skimmed milk in T-PBS for 1 h in agitation at RT and incubated with primary
antibody in 5% skimmed milk in T-PBS overnight in agitation at 4 C. The anti-
bodies used were: mouse anti-MyHC 1:2 for cultured cells, 1:10,000 for tissues
(MF20-Hybridoma Bank), mouse anti-MyoD 1:1,000 (Dako), rabbit anti-Myf5
1:500 (Tebu-Bio), mouse anti-Myogenin 1:3 (IF5D- Hybridoma Bank), mouse
anti-dystrophin 1:500 (Monosan), mouse anti-Pax3 1:2 (Hybridoma Bank), mouse
anti-Pax7 1:3 (Hybridoma Bank), mouse anti-cycE 1:1,000 (Santa Cruz), rat anti
JAM-A32 1:250, mouse anti b-tubulin 1:5,000 (Covance), mouse anti-GAPDH
1:5,000 (Biogenesis), mouse-Vinculin 1:2,500 (Sigma-Aldrich). After the primary
incubation, the membrane was washed four times for 10min each with T-PBS at
RT in agitation. Then it was incubated with secondary antibody conjugated to
peroxidase 1:10,000 (Bio-Rad) in 5% skimmed milk in T-PBS for 45min at RT in
agitation. After four washes for 10min each with T-PBS at RT in agitation, the
membrane was incubated in ECL chemiluminiscence reagents following the
manufacturer’s instructions (Amersham).
All the uncropped scan of western blots are shown in Supplementary
Information.
ChiP assay. For the ChiP assay, 3 106 AdmMABs were maintained in growth
condition for 2 days. Protein-DNA was crosslinked with a solution of 1% for-
maldehyde (Sigma-Aldrich) in DMEM for 10min. Crosslink was blocked with
0.125M glycine (Sigma-Aldrich) in PBS, for 10min while shaking. After two
washes with PBS, cells were scraped with PBS containing protease inhibitors and
PMSF. The suspension was centrifuged for 15min at 1,500 g, 4 C, the supernatant
removed and the cell pellet was dounced 20 times in a 7ml pestle dounce in
swelling buffer. Swollen cells were then centrifuged for 10min at 5,000 g, 4 C and
the nuclei pellets were sonicated on ice-cooled water with a Bioruptor Sonicator
(Diagenode) for a total of 15min, with repeated cycles of 15 s of sonication time
and 15 s of resting. Samples were ﬁnally centrifuged for 10min at 12,000 g, 4 C to
eliminate cell debris. Chromatin-enriched supernatant was precleared for 2 h with
protein G Sepharose (PrG, 15ml per sample) (Amersham) and rabbit serum (2,5 ml
per sample), then for 2 h with PrG previously blocked with BSA (10 mgml 1)
and salmon sperm (1 mgml 1, Sigma-Aldrich), on a rotating platform at 4 C.
Chromatin was than incubated overnight with the following primary antibodies
(3mg for each immunoprecipitation): rabbit anti-PW133, normal rabbit IgG
(SantaCruz). The day after, immunocomplexes were precipitated by addition of
blocked PrG, for 3 h on rotating platform at 4 C. After immunoprecipitation,
samples were centrifuged for 2min at 12,000 g, 4 C. Samples were then repeatedly
washed to eliminate aspeciﬁc bindings. The antibody–protein-DNA complexes
were eluted twice for 10min at 65 C. Eluted samples were incubated overnight at
65 C with 10mg RNase (Sigma-Aldrich) and 200mM NaCl (Sigma-Aldrich), to
reverse formaldehyde crosslinks. Finally, DNA was puriﬁed from proteins with a
Proteinase K (Sigma-Aldrich) treatment (20 mg per sample) for 3 h at 50 C, and
then DNA extracted through phenol–chloroform. Immunoprecipitated DNA was
subjected to qRT–PCR. The primers used are detailed in the Supplementary
Table 2.
Luciferase activity detection. The pLuciferase-cycE  94/þ 263 (pCE),
published in ref. 28, and pCMVHAE2F-2 (E2F-2) were kindly provided by
G. Piaggio (IRE, Rome) and M. Crescenzi (ISS, Rome), respectively. pGL4.76
was purchased by Promega. NIH3T3 cells were co-transfected with pCE, E2F-2,
pGL4.72 with or without PW1 according to the Lipofectamine 2000 manufacturer’s
protocol (Invitrogen). The pGL4.76 vector was used as an internal control
for transfection efﬁciency. Luciferase activity was detected according to the
Dual-Luciferase Reporter Assay System (Promega).
In vitro transmigration assay. The 8 mm transwell ﬁlters (Corning) were pre-
viously coated with glutaraldehyde-crosslinked gelatin to enhance endothelial cell
adhesion: the culture supports were incubated for 1 h at RT with 0.5% (for murine
endothelial cells) or 1.5% (for HUVECs) gelatin (Sigma-Aldrich), followed by
crosslinking with 2% glutaraldehyde solution (Sigma-Aldrich) for 15min at RT.
The glutaraldehyde was then replaced by 70% ethanol. After 1 h, ﬁve washes with
sterile PBS were followed by an overnight incubation with PBS containing 2mM
glycine. Before cell seeding, the slides were washed ﬁve times with sterile PBS.
Endothelial cells H5V were plated to conﬂuence in insert for 24 h. Ctl, shPW1,
competent and non-competent AdmMABs, previously transduced with a Lentiviral
vector expressing the nuclear LacZ, were plated in DMEM supplemented with 2%
horse serum (Lonza) on the upper side of transwell chamber once the monolayer of
H5V cells was complete (conﬂuence of the endothelial monolayer was assessed by
crystal-violet staining). After 11 h, migrated MABs on the lower side of the ﬁlter
were ﬁxed in 4% paraformaldehyde, stained with X-gal and counted using a phase
microscope (ﬁve random ﬁelds of the lower face of the transwell membrane at
 10 magniﬁcation).
HUVECs were plated to conﬂuence in insert for 72 h. Human MABs were
labelled with 3.33 mM 6-carboxyﬂuorescein diacetate (Molecular Probes,
Invitrogen) for 20min at 37 C. The ﬂuorescent human MABs were added to the
upper chamber in DMEM supplemented with 2% horse serum (Lonza). After 8 h,
migrated MABs on the lower side of the ﬁlter were ﬁxed in 4% paraformaldehyde
and counted using a ﬂuorescence microscope (ﬁve random ﬁelds of the lower face
of the transwell membrane at  10 magniﬁcation).
For the in vitro transmigration assay in the presence of monoclonal anti-mouse
(clone BV11 (ref. 27)) or human JAM-A (clone BV16 (ref. 27)) MABs, both mouse
or human MABs were pre-treated with the monoclonal anti-JAM-A antibody
(BV11 at 20mgml 1 and BV16 at 12mgml 1) and human JAM-A in DMEM
supplemented with 0,5% FBS for 2 h at 37 C. After incubation, the cells were
plated on the upper side of a transwell chamber and the lower side was
supplemented with DMEM 0.5% FBS with the anti-JAM-A antibody. After 11 (for
mMABs) or 8 (for hMABs) hours, migrated MABs on the lower side of the ﬁlter
were ﬁxed in 4% paraformaldehyde and counted using a microscope (ﬁve random
ﬁelds of the lower face of the transwell membrane at  10 magniﬁcation). The
results show the number of migrated cells per mm2.
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